Who makes Argatroban combined with rt-PA?

Argatroban combined with rt-PA is developed by Hui-Sheng Chen.

What development phase is Argatroban combined with rt-PA in?

Argatroban combined with rt-PA is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Argatroban combined with rt-PA

Hui-Sheng Chen · FDA-approved active Small molecule Quality 3/100

At a glance

Generic name	Argatroban combined with rt-PA
Sponsor	Hui-Sheng Chen
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Argatroban Plus R-tPA for Acute Ischemic Stroke (PHASE4)
Argatroban Plus r-tPA for Posterior Circulation Infarction（AR-PCI） (PHASE4)
Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke (PHASE2)
Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Argatroban combined with rt-PA CI brief — competitive landscape report
Argatroban combined with rt-PA updates RSS · CI watch RSS
Hui-Sheng Chen portfolio CI